Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
Front Endocrinol (Lausanne). 2023 Aug 4;14:1217092. doi: 10.3389/fendo.2023.1217092. eCollection 2023.
The clinical features and prognosis of children and adolescents with differentiated thyroid carcinoma (caDTC) are different from that of adults. Postoperative radioiodine therapy (RIT) was recommended for some intermediate and high risk caDTC patients. The objective of this study was to evaluate the long-term prognosis of pediatric caDTC patients with different responses to initial RIT and to explore the related influencing factors.
All subjects were assigned to no clinical evidence of disease (NED) group, biochemical persistent disease (BPD) group, or structural/functional persistent disease (S/FPD) group based on the therapeutic response to initial RIT. Then, disease status was evaluated in all three groups at the last follow-up using ATA guidelines. Meanwhile, disease-free survival (DFS) for NED group and the progression-free survival (PFS) for the BPD and S/FPD groups were also assessed.
117 subjects were divided into NED group (n=29), BPD group (n=48) and S/FPD group (n=34) after initial RIT. At the last follow-up, excellent response (ER), indeterminate response (IDR), biochemically incomplete response (BIR) and structurally incomplete response (SIR) rates were 93.10%, 6.90%, 0% and 0% in NED group; 29.17%, 25.00%, 43.75% and 2.08% in BPD group; and 11.77%, 2.94%, 0%, and 85.29% in S/FPD group. The 5-year DFS rate in NED group was 95.5%. The 5-year PFS rates in BPD and S/FPD groups were 79.2% and 48.6%, respectively. For children with structural or functional lesions, longer PFS were found in male children with I-avid lesions, and post-operative stimulated serum thyroglobulin (sti-Tg) < 149.80 ng/ml.
The response to initial RIT could be helpful for defining subsequent treatment and follow-up strategies for caDTC patients. Post-operative sti-Tg and I-avidity of lesions are correlated with PFS.
儿童和青少年分化型甲状腺癌(caDTC)的临床特征和预后与成人不同。对于一些中高危 caDTC 患者,建议术后进行放射性碘治疗(RIT)。本研究的目的是评估不同初始 RIT 反应的儿科 caDTC 患者的长期预后,并探讨相关影响因素。
根据初始 RIT 治疗的反应,所有患者均被分为无临床证据疾病(NED)组、生化持续性疾病(BPD)组或结构性/功能性持续性疾病(S/FPD)组。然后,根据 ATA 指南,在最后一次随访时评估所有三组的疾病状态。同时,评估 NED 组的无病生存(DFS)和 BPD 和 S/FPD 组的无进展生存(PFS)。
117 例患者经初始 RIT 后分为 NED 组(n=29)、BPD 组(n=48)和 S/FPD 组(n=34)。在最后一次随访时,NED 组的优秀反应(ER)、不确定反应(IDR)、生化不完全反应(BIR)和结构性不完全反应(SIR)率分别为 93.10%、6.90%、0%和 0%;BPD 组分别为 29.17%、25.00%、43.75%和 2.08%;S/FPD 组分别为 11.77%、2.94%、0%和 85.29%。NED 组的 5 年 DFS 率为 95.5%。BPD 和 S/FPD 组的 5 年 PFS 率分别为 79.2%和 48.6%。对于结构性或功能性病变的患儿,I 阳性病灶的男性患儿有更长的 PFS,术后刺激血清甲状腺球蛋白(sti-Tg)<149.80ng/ml。
初始 RIT 反应有助于确定 caDTC 患者的后续治疗和随访策略。术后 sti-Tg 和病灶的 I 活性与 PFS 相关。